Dr. Jacobo E. Mintzer, MD
Psychiatry (Psychiatry Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
SC license 16312
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 3 companies reported 6 payments worth $17,936 in total to this clinician.
| Axsome Therapeutics, Inc. | $9,104 |
|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $5,832 |
| Acadia Pharmaceuticals Inc | $3,000 |
| Honoraria | $8,438 |
|---|---|
| Consulting Fee | $5,832 |
| Compensation for services other than consulting (speaking, faculty) | $3,000 |
| Travel and Lodging | $666 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. Aug 13, 2025 | Honoraria | $8,438 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Jan 24, 2025 | Consulting Fee | $5,832 |
| Acadia Pharmaceuticals Inc May 29, 2025 | Compensation for services other than consulting (speaking, faculty) ACP-204 · ALZHEIMERS DISEASE PSYCHOSIS | $1,200 |
| Acadia Pharmaceuticals Inc Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) NUPLAZID · PARKINSONS DISEASE PSYCHOSIS | $1,200 |
| Axsome Therapeutics, Inc. Jul 25, 2025 | Travel and Lodging travel to Toronto, ON, Canada · in-kind | $666 |
| Acadia Pharmaceuticals Inc Oct 13, 2025 | Compensation for services other than consulting (speaking, faculty) ACP-204 · ALZHEIMERS DISEASE PSYCHOSIS | $600 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $797,931 in research payments for these studies, mostly to the institutions running them.
- A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) an…
Eisai Inc. - A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease
Eisai Inc. - A Trial of the Safety, Tolerability, and Pharmacodynamics of CVL-871 in Subjects With Dementia-Related Apathy
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.